Dublin, April 28, 2023 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates (ADCs) in Oncology- Competitive Landscape - 2023" report has been added to ResearchAndMarkets.com's offering.
This "Antibody-drug Conjugates (ADCs) Competitive landscape, 2023" report provides comprehensive insights about 30+ companies and 35+ drugs in ADCs. It covers the therapeutics assessment by product type, stage, route of administration, dosage, and dosing frequency. The report highlights the entire competitive landscape of both marketed and pipeline products in this space.
Report Highlights
- Detailed insights on 10+ ADCs that have achieved market authorization in the US since the US Food and Drug Administration (FDA) approved the first ADC, MYLOTARG (gemtuzumab ozogamicin), in 2000 and future aspects of ADCs, which are still in the development stages - related to their current phase and upcoming events.
- The introduction of ADCs into the market and the promising clinical results of more ADC prospects have increased industry interest in ADCs as a treatment strategy. Our report showcases an explication and analysis of top ADCs in revenue like KADCYLA, ADCETRIS, ENHERTU, TRODELVY, and others, which are currently ruling the market.
- Breast and lung cancer are the top two cancers offering a wide patient pool to target, among which breast cancer has the highest prevalence. However, the lung cancer treatment space is more active with several mid to late-stage ADCs.
- Daiichi and AstraZeneca plan to further broaden ENHERTU's application scope to expand its market scale - this clearly shows the growing interest of big pharma giants and small biotech companies in expanding their focus on ADCs, paving the way for a new age of targeted cancer treatment. In the report, we provide in-depth elucidations of key players portfolios, strategies, and forthcoming plans in the ADC landscape.
- Seagen, Daiichi Sankyo, AstraZeneca, ADC Therapeutics, and Abbvie are the leading players with the highest ADC clinical developments. Among the emerging key players, the hit combo Daiichi Sankyo/AstraZeneca is actively involved in lung and breast cancer therapy with their top-drawer drug datopotamab deruxtecan, followed by others like Sanofi and AbbVie.
Company Profiles and Their Late-stage Drug Profiles
ADCs are complex therapeutics with unique pharmacokinetic profiles and mechanisms of action and resistance that are yet to be fully understood. Despite their vast potential to be 'magic missiles' in cancer, ADCs have presented a huge challenge to researchers, particularly around getting the formula to balance the three parts right.
With the continuous efforts by researchers in these fields, it is not difficult to envisage that future ADCs will show more surprises in targeted therapy in oncology and non-oncology indications.
The success of these third-generation drugs has grabbed the attention of top-notch companies in the ADCs development space. This segment of the report overlooks the pipeline and strategies adopted by various companies that are lively indulged in ADC development activities and provides deep insights into their early to late-stage products in this domain.
Owing to the growing prevalence and better overall survival rates, lung and breast cancer treatment spaces are the major target platform for ADC developers.
In-depth ADCs analysis: Assessment of Products
- The report provides insights on the commercial assessment of drugs included, including collaboration, agreement, licensing, and acquisition - deals values trends. The report describes the sub-segmentation that provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.
Antibody-drug Conjugates in Oncology Clinical Assessment of Products
The report comprises a comparative clinical assessment of products by development stage, product type, route of administration, dosage, and dosing frequency.
- ADCs Report Assessment
- ADCs Company Analysis
- ADCs Therapeutic Assessment
- ADCs Pipeline Assessment
- ADCs Unmet Needs
- ADCs Competitors Analysis
- ADCs SWOT Analysis
Key Questions Answered
- Which are the key leading companies engaged in the clinical development of ADCs?
- What is the status of the ongoing clinical trials? How many emerging ADCs are currently in the early, middle, and late stages of development?
- What are the key collaborations (industry-industry, industry-academia), mergers and acquisitions, and licensing activities related to developing ADCs as a therapy?
- What strategies are adopted to overcome the safety concerns associated with first-generation ADCs - a major limitation of approved therapies?
- What key designations have been granted to both emerging and approved ADCs and their benefits in ADC development?
- What are the major influential factors that can either impede or enhance the clinical development of ADCs?
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Key Highlights From the Report
4. Executive Summary of Antibody-drug Conjugates (ADCs) in Oncology
5. Key Events
6. Market Forecast Methodology
7. Antibody-drug Conjugates (ADCs) in Oncology Market Overview at a Glance in the 7MM
7.1. Market Share (%) Distribution by Indications in 2022
7.2. Market Share (%) Distribution by Indications in 2032
8. Disease Background and Overview
9. Marketed Drugs
9.1. Key Competitors
9.2. Marketed Antibody-drug Conjugates (ADCs) in Breast Cancer
9.2.1. TRODELVY (sacituzumab govitecan-hziy): Gilead Sciences
9.3. Marketed Antibody-drug Conjugates (ADCs) in Lung Cancer
List to be continued in the report.
10. Emerging Drugs
10.1. Key Competitors
10.2. Emerging Antibody-drug Conjugates (ADCs) in Breast Cancer
10.2.1. Trastuzumab duocarmazine (SYD985): Byondis
10.3. Emerging Antibody-drug Conjugates (ADCs) in Lung Cancer
11. Antibody-drug Conjugates (ADCs) in Oncology: 7MM analysis
11.1. Key Findings
11.2. Market Outlook
11.3. Key Market Forecast Assumptions
11.4. Indication-wise Market size of Antibody-drug Conjugates (ADCs) in Oncology in the 7MM
11.5. Market Size of Antibody-drug Conjugates (ADCs) in Oncology by Therapies in the 7MM
11.6. United States Market Size
11.6.1. Indication-wise market size of Antibody-drug Conjugates (ADCs) in Oncology in the United States
11.6.2. Total market size of Antibody-drug Conjugates (ADCs) in Oncology by therapies in the United States
11.7. EU4 and the UK Market Size
11.7.1. Indication-wise market size of Antibody-drug Conjugates (ADCs) in Oncology in EU4 and the UK
11.7.2. Market size of Antibody-drug Conjugates (ADCs) in Oncology by therapies in EU4 and the UK
11.8. Japan Market Size
11.8.1. Indication-wise market size of Antibody-drug Conjugates (ADCs) in Oncology in Japan
11.8.2. Market size of Antibody-drug Conjugates (ADCs) in Oncology by therapies in Japan
12. Unmet Needs
13. SWOT Analysis
14. KOL Views
15. Market Access and Reimbursement
16. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/820oxh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
